SCHEMBL313784

SCHEMBL313784

C[N+]1(Cc2ccc(NC(=O)/C=C/c3ccc(Cl)c(Cl)c3)cc2)CCCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 2/20 0.66
CCR2 P41597 1/20 0.56
DHODH Q02127 1/20 0.55
MAPT P10636 5/20 0.51
TP53 P04637 2/20 0.51
PYGL P06737 7/20 0.49
MCHR1 Q99705 2/20 0.47
CHRM1 P11229 1/20 0.47
HTR2A P28223 1/20 0.47
NPC1 O15118 1/20 0.46
PKM P14618 1/20 0.46
RAB9A P51151 1/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
MCL1 Q07820 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313785 1.00 CCR5 (0.66) CCR5CCR2DHODHMAPTTP53
Iodide SCHEMBL3086681 0.99 CCR5 (0.67) CCR5CCR2DHODHMAPTTP53
Iodide SCHEMBL3086683 0.99 CCR5 (0.67) CCR5CCR2DHODHMAPTTP53
Hydrochloric Acid SCHEMBL2908323 0.99 CCR5 (0.65) CCR5CCR2DHODHMAPTTP53
Hydrochloric Acid SCHEMBL2908319 0.99 CCR5 (0.65) CCR5CCR2DHODHMAPTTP53
SCHEMBL2696192 0.89 CCR2 (0.64) CCR5CCR2DHODHMAPTTP53
SCHEMBL2696196 0.89 CCR2 (0.64) CCR5CCR2DHODHMAPTTP53
Iodide SCHEMBL17555092 0.89 CCR2 (0.63) CCR5CCR2DHODHMAPTTP53
Hydrochloric Acid SCHEMBL2906194 0.89 CCR2 (0.63) CCR5CCR2DHODHMAPTTP53
Hydrochloric Acid SCHEMBL2906196 0.89 CCR2 (0.63) CCR5CCR2DHODHMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168829-B2 Synthesis of quaternary salt compounds JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-01 US disclosed
US-8093428-B2 Synthesis of quaternary salt compounds JANSSEN PHARMACEUTICA N.V. (BE) 2012-01-10 US disclosed
US-7799824-B2 Quaternary salt CCR2 antagonists ORAPHARMA, INC. (US) 2010-09-21 US disclosed
US-20090112003-A1 SYNTHESIS OF QUATERNARY SALT COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed
US-20090112004-A1 SYNTHESIS OF QUATERNARY SALT COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090112003-A1 SYNTHESIS OF QUATERNARY SALT COMPOUNDS CCR2, CCR1, CCL11 CCR5 7/4885CCR2 1/4885DHODH 573/4885
US-20090112004-A1 SYNTHESIS OF QUATERNARY SALT COMPOUNDS CCR2, CCR1, CCL11 CCR5 7/4885CCR2 1/4885DHODH 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.